Recurrent diffuse midline glioma, H3 K27-altered

Clinical trials for Recurrent diffuse midline glioma, H3 K27-altered explained in plain language.

Never miss a new study

Get alerted when new Recurrent diffuse midline glioma, H3 K27-altered trials appear

Sign up with your email to follow new studies for Recurrent diffuse midline glioma, H3 K27-altered, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New hope for kids with relapsed cancers: experimental drug CBL0137 enters trial

Disease control Recruiting now

This study tests a new drug called CBL0137 in children and young adults (ages 1 to 21) whose solid tumors, brain tumors, or lymphoma have returned or stopped responding to treatment. The goal is to find the best dose, check side effects, and see if the drug can shrink tumors. The…

Matched conditions: RECURRENT DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED

Phase 1/2 • Sponsor: Children's Oncology Group • Aim: Disease control

Last updated Sep 13, 2026 00:00 UTC

Recurrent diffuse midline glioma, H3 K27-altered

Get alerted when new Recurrent diffuse midline glioma, H3 K27-altered trials appear

New hope for kids with relapsed cancers: experimental drug CBL0137 enters trial